Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CF-301 Phase 1 in healthy subjects
NCT02439359Phase 1Completed
- Sponsor
- ContraFect Corporation
- Start
- May 2015
- Primary completion
- Dec 2015
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Staphylococcus aureus bloodstream infection (SABSI) and infective endocarditis (IE) comparing CF-301 with Placebo (2 arms). Primary endpoint: Safety and tolerability as measured by AE's up to 8 months. Started May 2015; status: completed.
02
Drugs
exebacase
03
Conditions
Staphylococcus aureus bloodstream infection (SABSI)infective endocarditis (IE)
Beyond the preview
Go deeper on NCT02439359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02439359.